Heather Florio joins to discuss the potential role of supplements in pelvic and sexual health.
|Videos|February 24, 2022
Dr. Schuster discusses trial of 18F-rhPSMA-7.3 in prostate cancer
Author(s)Urology Times staff
Advertisement
In this video, David M. Schuster, MD, FACR, discusses the background and findings of the study, “Detection rates of 18F-rhPSMA-7.3 PET in patients with suspected prostate cancer recurrence: results from a phase 3, prospective, multicenter study (SPOTLIGHT),” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Schuster is a professor of urology and radiology and imaging sciences, a GRA distinguished cancer scientist, and the director of the division of nuclear medicine and molecular imaging at the Emory University School of Medicine in Atlanta, Georgia.
Advertisement
Related to this article
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
A recap of the FDA submissions and regulatory decisions in urology from September 2026.
Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
In RTOG 3506, adding enzalutamide to standard ADT and salvage radiotherapy was associated with 2-year PFS benefit.
Armine K. Smith, MD, discusses the importance of integrating sexual health into bladder cancer care, including proactive counseling, preservation strategies, and multidisciplinary support.
Advertisement
Advertisement
Trending on Urology Times
1
FDA updates in urology: September 2026
2
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
3
SBRT, prostatectomy show comparable long-term disease control in PACE-A trial
4
Behind the FDA approval of belzutifan plus lenvatinib in advanced ccRCC, with Robert Motzer, MD
5